Drug Delivery Platforms
•229 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (229)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Drug delivery platforms are highlighted as differentiators enabling scaled manufacturing.
|
$935.10B |
$930.77
-5.90%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Drug delivery platform concepts (e.g., formulation/formulation technologies) are implied by delivery enhancements.
|
$79.55B |
$758.82
+0.25%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$45.74B |
$161.72
+0.90%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY employs drug delivery platforms (e.g., GalNAc conjugates) enabling targeted and durable RNAi delivery.
|
$42.13B |
$320.21
+0.41%
|
|
INSM
Insmed Incorporated
ARIKAYCE uses a liposomal inhalation drug-delivery platform (Pulmovance) and TPIP is an inhaled prodrug, making Drug Delivery Platforms a core Insmed technology.
|
$30.84B |
$143.97
-0.44%
|
|
BNTX
BioNTech SE
Drug Delivery Platforms cover mRNA delivery and related platforms used to deploy therapies.
|
$21.77B |
$94.91
+4.83%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$15.80B |
$230.49
+2.60%
|
|
ASND
Ascendis Pharma A/S
TransCon is a proprietary drug-delivery platform enabling long-acting formulations, aligning with Drug Delivery Platforms.
|
$14.12B |
$228.16
-1.24%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's low-sodium formulation (Xywav) reflects a Drug Delivery Platform approach.
|
$11.06B |
$181.29
-0.40%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.47B |
$129.51
+0.36%
|
|
AXSM
Axsome Therapeutics, Inc.
MoSEIC drug-delivery platform powering Symbravo indicates reliance on Drug Delivery Platforms.
|
$7.98B |
$161.24
+1.90%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
TRiM is a drug delivery platform enabling targeted siRNA delivery beyond the liver.
|
$7.79B |
$57.56
+0.33%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$7.56B |
$65.15
+1.34%
|
|
MTSR
Metsera, Inc.
HALO and MOMENTUM are proprietary drug-delivery platforms enabling extended half-life and oral peptide delivery, i.e., Drug Delivery Platforms.
|
$7.41B |
$70.53
+0.04%
|
|
KRYS
Krystal Biotech, Inc.
Krystal's HSV-1 platform functions as a drug-delivery platform enabling redosable gene therapies across organs.
|
$7.25B |
$256.40
+2.49%
|
|
PTGX
Protagonist Therapeutics, Inc.
Platform-based drug delivery approach enabling peptide therapeutics.
|
$6.05B |
$97.23
+0.50%
|
|
GKOS
Glaukos Corporation
iDose TR represents a drug delivery platform delivering a sustained intraocular Travoprost formulation.
|
$5.68B |
$103.00
+4.10%
|
|
CDTX
Cidara Therapeutics, Inc.
Cloudbreak is a drug delivery platform (Drug-Fc Conjugate) enabling extended half-life and targeted activity.
|
$5.61B |
$221.39
+0.00%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$4.65B |
$15.39
+0.26%
|
|
ALKS
Alkermes plc
Proprietary drug delivery platforms (e.g., LinkeRx, NanoCrystal) used to create extended-release and rapid-dissolution formulations.
|
$4.62B |
$27.68
-1.16%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.11B |
$40.69
+1.06%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.09B |
$211.12
+1.60%
|
|
INDV
Indivior Pharmaceuticals Inc
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$3.87B |
$31.32
+1.13%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal's focus on drug delivery platforms spans multiple complex dosage forms and delivery technologies.
|
$3.75B |
$12.43
+4.06%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics' NDC platform and drug-conjugate strategy reflect a drug-delivery platform providing targeted payload delivery.
|
$3.54B |
$37.84
+1.50%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.11B |
$36.87
+3.28%
|
|
DNLI
Denali Therapeutics Inc.
The TransportVehicle platform is a drug delivery platform designed to cross the blood-brain barrier to deliver biologics to the CNS.
|
$3.02B |
$20.73
+0.78%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus leverages proprietary drug-delivery platforms, notably extended-release formulations, as a core differentiator for its CNS therapies.
|
$2.88B |
$50.84
+1.25%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$2.59B |
$18.64
+2.81%
|
|
BEAM
Beam Therapeutics Inc.
Beam uses lipid nanoparticle (LNP) delivery for in vivo base editing (BEAM-302, BEAM-301), i.e., a Drug Delivery Platform.
|
$2.59B |
$25.83
+1.33%
|
|
ETNB
89bio, Inc.
The company relies on a glycoPEGylation-based drug delivery platform to extend half-life and dosing convenience, representing a Drug Delivery Platforms investable theme.
|
$2.17B |
$14.85
+0.07%
|
|
AVDL
Avadel Pharmaceuticals plc
Avadel uses a proprietary polymer-based extended-release drug-delivery platform to create once-nightly LUMRYZ.
|
$2.10B |
$21.66
+0.09%
|
|
WVE
Wave Life Sciences Ltd.
PRISM delivers oligonucleotides via conjugates (e.g., GalNAc) and non-viral delivery, constituting a drug delivery platform.
|
$2.07B |
$12.46
+0.44%
|
|
CLDX
Celldex Therapeutics, Inc.
Drug delivery platforms and subcutaneous formulations are part of Celldex's formulation strategy.
|
$2.01B |
$29.64
-1.82%
|
|
IMNM
Immunome, Inc.
HC74 payload and linker optimization reflect a drug delivery platform approach.
|
$1.87B |
$20.71
+1.72%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.84B |
$8.66
+0.41%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's use of a proprietary oral-dispensing drug-delivery technology constitutes a Drug Delivery Platform.
|
$1.80B |
$18.08
+2515.36%
|
|
SLNO
Soleno Therapeutics, Inc.
Drug Delivery Platforms reflects VYKAT XR's extended-release formulation and dosing advantage.
|
$1.79B |
$33.64
+0.75%
|
|
ZYME
Zymeworks Inc.
Drug Delivery Platforms underpin ADC and multispecific payload engineering and delivery.
|
$1.77B |
$24.06
+1.86%
|
|
SRPT
Sarepta Therapeutics, Inc.
Drug Delivery Platforms underpin Sarepta's delivery of gene therapies and RNAi assets.
|
$1.75B |
$16.84
+1.11%
|
|
NVAX
Novavax, Inc.
Matrix-M is a proprietary vaccine adjuvant/drug-delivery platform used across Novavax's vaccine programs, constituting a major platform technology.
|
$1.64B |
$10.64
+5.56%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Development of drug delivery platforms (e.g., Cortrophin Gel pre-filled syringe) demonstrates ANI's drug delivery technology differentiators.
|
$1.62B |
$74.25
+2.88%
|
|
NBTX
Nanobiotix S.A.
Curadigm and Oocuity are nanoparticle-based platforms aimed at drug delivery and neurally targeted effects, aligning with Drug Delivery Platforms.
|
$1.61B |
$32.01
-5.85%
|
|
NTLA
Intellia Therapeutics, Inc.
Proprietary drug-delivery platform (LNP) enabling in vivo gene editing across programs.
|
$1.55B |
$13.50
+0.90%
|
|
NUVB
Nuvation Bio Inc.
NUV-1511 is based on a Drug-Delivery Platform (DDC), directly describing a drug delivery platform product.
|
$1.55B |
$4.38
-2.56%
|
|
PHVS
Pharvaris N.V.
Pharvaris emphasizes oral delivery with injectable-like efficacy, indicating a Drug Delivery Platforms orientation.
|
$1.47B |
$26.96
+0.11%
|
|
NKTR
Nektar Therapeutics
PEGylation is a drug-delivery platform approach used to optimize pharmacokinetics and dosing.
|
$1.47B |
$75.05
+3.93%
|
|
PVLA
Palvella Therapeutics, Inc.
QTORIN represents a drug delivery platform for localized, topical therapy, a major category in pharmaceutical technology and patient-specific treatments.
|
$1.47B |
$131.44
-0.89%
|
|
OCS
Oculis Holding AG
OPTIREACH is a drug delivery platform enabling topical therapies to reach the posterior segment.
|
$1.45B |
$26.88
+3.31%
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$1.40B |
$31.16
+1.98%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$1.35B |
$9.48
-2.02%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX is using a drug delivery platform (PEP) to extend action of peptides, enabling less frequent dosing, fitting Drug Delivery Platforms.
|
$1.34B |
$29.71
-0.29%
|
|
KOD
Kodiak Sciences Inc.
ABC/ABCD platforms are drug delivery technologies enabling sustained ocular release and extended durability.
|
$1.23B |
$23.86
+2.36%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Core platform technology (Durasert E) used for sustained ocular drug delivery.
|
$1.11B |
$13.90
+3.35%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY is a drug delivery platform designed to localize activity to tumors, fitting Drug Delivery Platforms.
|
$1.11B |
$5.44
-19.41%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
CVAC
CureVac N.V.
Drug Delivery Platforms captures CureVac's proprietary LNP delivery systems and thermostable formulations integral to its mRNA programs.
|
$1.05B |
$4.66
|
|
PGEN
Precigen, Inc.
Drug Delivery Platforms tag applies to platform-based delivery mechanisms like AdenoVerse and UltraCAR-T.
|
$1.05B |
$3.53
+0.57%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP and related platforms constitute drug-delivery platforms enabling targeted degradation of extracellular proteins.
|
$1.02B |
$9.53
-1.14%
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.00B |
$69.45
+0.28%
|
|
SVRA
Savara Inc.
Delivery via inhalation (Drug Delivery Platform) is a core aspect of MOLBREEVI's administration method.
|
$1.00B |
$5.58
-3.79%
|
|
VERV
Verve Therapeutics, Inc.
Verve's platform GalNAc-LNP is a proprietary drug delivery system used to target liver cells for gene-editing therapies.
|
$988.30M |
$11.13
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$976.15M |
$21.92
-3.39%
|
|
TBPH
Theravance Biopharma, Inc.
YUPELRI's nebulized delivery represents a drug delivery platform differentiator for a respiratory therapy.
|
$969.96M |
$19.09
-0.86%
|
|
ABUS
Arbutus Biopharma Corporation
Their LNP delivery technology is a drug delivery platform underpinning their RNAi assets.
|
$948.91M |
$4.58
-7.58%
|
|
GHRS
GH Research PLC
GH Research employs an inhalable drug delivery approach for GH001, representing a Drug Delivery Platforms capability.
|
$937.26M |
$15.32
+1.42%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$919.51M |
$4.16
-3.03%
|
|
OPK
OPKO Health, Inc.
Entera Bio collaboration for oral formulation indicates an emphasis on drug delivery platforms.
|
$913.56M |
$1.20
+0.42%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$910.92M |
$5.62
+2.37%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Drug Delivery Platforms captures Amphastar's proprietary delivery systems for injectables, inhalation, and intranasal therapies.
|
$891.93M |
$19.53
+0.62%
|
|
URGN
UroGen Pharma Ltd.
RTGel is a drug-delivery platform used by UroGen for localized, extended-release therapy.
|
$876.73M |
$18.57
-0.85%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
Phathom is pursuing an orally disintegrating tablet (ODT) formulation and other delivery innovations for VOQUEZNA, aligning with the drug delivery platforms investable theme.
|
$742.69M |
$10.86
+3.98%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$718.60M |
$2.35
|
|
PRME
Prime Medicine, Inc.
Leverages a drug delivery platform (universal liver LNP with GalNAc targeting) to enable in vivo gene editing.
|
$662.47M |
$3.72
+1.36%
|
|
DSGN
Design Therapeutics, Inc.
GeneTAC platform implies a drug delivery/modulation approach, aligning with a Drug Delivery Platforms category.
|
$626.03M |
$11.04
+0.45%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
MGTX
MeiraGTx Holdings plc
Riboswitch platform represents a drug delivery platform enabling regulated transgene expression, a core technology.
|
$607.38M |
$7.40
-1.99%
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$577.34M |
$6.98
-5.16%
|
|
KE
Kimball Electronics, Inc.
Drug delivery platforms are a targeted medical technology offering within KE's Medical CMO scope.
|
$566.35M |
$23.34
+0.30%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$557.62M |
$19.79
-2.78%
|
|
ADCT
ADC Therapeutics S.A.
ADCT emphasizes a proprietary Drug Delivery Platform powering its ADC payloads and conjugation chemistries.
|
$522.76M |
$4.10
-2.84%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$509.97M |
$4.12
-1.32%
|
|
ANRO
Alto Neuroscience, Inc.
Drug delivery platform to enable targeted or improved administration of Alto's CNS therapeutics (e.g., transdermal PDE4 inhibitor).
|
$495.50M |
$19.34
+5.71%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$486.91M |
$12.59
-1.18%
|
|
ENGN
enGene Holdings Inc.
DDX platform is a drug delivery technology enabling localized genetic medicines, a distinct product category.
|
$484.30M |
$7.26
+0.41%
|
|
ZVRA
Zevra Therapeutics, Inc.
LAT platform enables prodrug drug delivery platforms, representing a proprietary drug-delivery platform technology.
|
$466.48M |
$8.48
+2.05%
|
|
FLGT
Fulgent Genetics, Inc.
Drug delivery platforms including nanoencapsulation.
|
$462.14M |
$15.44
+3.28%
|
|
RGNX
REGENXBIO Inc.
NAV platform involves drug delivery platform technology.
|
$444.98M |
$8.64
-1.71%
|
|
BNTC
Benitec Biopharma Inc.
The Silence and Replace platform includes a drug delivery vector approach, fitting Drug Delivery Platforms.
|
$406.69M |
$11.76
-2.08%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's Therapeutic Vector Evolution platform constitutes a drug delivery platform enabling targeted, durable gene therapy delivery.
|
$396.04M |
$8.60
+1.42%
|
|
AURA
Aura Biosciences, Inc.
Aura's VDC platform is a drug delivery platform enabling targeted, light-activated therapy.
|
$393.22M |
$6.16
-2.69%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$392.89M |
$17.16
+4.54%
|
|
CATX
Perspective Therapeutics, Inc.
Developing a drug-delivery platform around the 212Pb radiopharmaceuticals and regional finishing capabilities.
|
$387.65M |
$4.96
-4.98%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 platform represents a drug delivery platform for radiopharmaceuticals, enabling targeted delivery and radionuclide conjugation.
|
$380.87M |
$56.59
-8.33%
|
|
LRMR
Larimar Therapeutics, Inc.
The CPP-based delivery platform is a core technology used to deliver nomlabofusp, i.e., Drug Delivery Platforms.
|
$376.60M |
$4.38
-0.34%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$373.92M |
$7.58
+2.57%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$371.13M |
$7.13
-0.70%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage emphasizes a drug delivery platform and formulation (cryopreserved thaw-and-inject formulations) enabling scalable, ready-to-administer cell therapies.
|
$368.52M |
$1.57
-1.56%
|
Showing page 1 of 3 (229 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
